Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268883 | 0.96 | PIK3CD (0.38) | PIK3CDTP53MAP2K1RAF1NPC1 | |
| SCHEMBL31268831 | 0.94 | PIK3CD (0.38) | PIK3CDTP53MAP2K1RAF1NPC1 | |
| SCHEMBL31269257 | 0.94 | PIK3CD (0.36) | PIK3CDTP53NPC1RAB9AMAPT | |
| SCHEMBL31268736 | 0.94 | PIK3CD (0.36) | PIK3CDTP53MAP2K1RAF1NPC1 | |
| SCHEMBL31268958 | 0.93 | PIK3CD (0.34) | PIK3CDMAP2K1RAF1 | |
| SCHEMBL31269065 | 0.93 | PIK3CD (0.35) | PIK3CDTP53NPC1RAB9AMAPT | |
| SCHEMBL31269232 | 0.91 | RAB9A (0.41) | PIK3CDTP53NPC1RAB9AMAPT | |
| SCHEMBL31269352 | 0.91 | PIK3CD (0.37) | PIK3CDTP53NPC1RAB9AMAPT | |
| SCHEMBL31269092 | 0.91 | RAB9A (0.40) | PIK3CDTP53NPC1RAB9AKMT2A | |
| SCHEMBL31269207 | 0.91 | PIK3CD (0.38) | PIK3CDTP53NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |